Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.

MLA

Pandya, Bhavik J., et al. “Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.” Advances in Therapy, vol. 36, no. 8, Aug. 2019, pp. 1922–35. EBSCOhost, https://doi.org/10.1007/s12325-019-01003-7.

APA

Pandya, B. J., Chen, C.-C., Medeiros, B. C., McGuiness, C. B., Wilson, S., Horvath Walsh, L. E., & Wade, R. L. (2019). Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database. Advances in Therapy, 36(8), 1922–1935. https://doi.org/10.1007/s12325-019-01003-7

Chicago

Pandya, Bhavik J, Chi-Chang Chen, Bruno C Medeiros, Catherine B McGuiness, Samuel Wilson, L Elise Horvath Walsh, and Rolin L Wade. 2019. “Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.” Advances in Therapy 36 (8): 1922–35. doi:10.1007/s12325-019-01003-7.